Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | HEXA | P06865 | 1/20 | 0.40 |
| ▸ | HEXB | P07686 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4446057 | 1.00 | GAA (0.83) | GAAALDH1A1CYP1A2CYP2C9RECQL | |
| SCHEMBL12144000 | 1.00 | GAA (0.83) | GAAALDH1A1CYP1A2CYP2C9RECQL | |
| SCHEMBL3251022 | 1.00 | GAA (0.83) | GAAALDH1A1CYP1A2CYP2C9RECQL | |
| SCHEMBL12028883 | 0.91 | GAA (1.00) | GAAALDH1A1CYP1A2CYP2C9RECQL | |
| SCHEMBL3077457 | 0.91 | GAA (1.00) | GAAALDH1A1CYP1A2CYP2C9RECQL | |
| SCHEMBL12029057 | 0.91 | GAA (1.00) | GAAALDH1A1CYP1A2CYP2C9RECQL | |
| SCHEMBL2452322 | 0.89 | GAA (0.69) | GAAALDH1A1CYP1A2CYP2C9RECQL | |
| SCHEMBL22326350 | 0.85 | GAA (0.88) | GAAALDH1A1CYP1A2CYP2C9RECQL | |
| SCHEMBL20363040 | 0.84 | GAA (0.86) | GAAALDH1A1CYP1A2CYP2C9RECQL | |
| SCHEMBL24181345 | 0.83 | GAA (0.83) | GAAALDH1A1CYP1A2CYP2C9RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4651906-A1 | ANTI-CD70 ANTIBODY-DRUG CONJUGATES | Ambrx, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| WO-2024178360-A2 | AURISTATIN ANALOGS AND ANTIBODY CONJUGATES THEREOF | AMBRX, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
| WO-2024178310-A1 | TROP2-DIRECTED ANTIBODY-DRUG CONJUGATES AND USES THEREOF | AMBRX, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
| WO-2024155627-A1 | ANTI-CD70 ANTIBODY-DRUG CONJUGATES | AMBRX, INC. (US) | 2024-07-25 | — | — | WO | disclosed |
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | AMBRX, INC. | 2024-07-16 | — | — | US | disclosed |
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | AMBRX, INC. | 2024-07-16 | — | — | US | disclosed |
| US-20240131168-A1 | NAPHTHALENE RING-CONTAINING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | ASIERIS PHARMACEUTICALS (SHANGHAI) CO., LTD. (CN) | 2024-04-25 | — | — | US | disclosed |
| EP-4339181-A1 | NAPHTHALENE RING-CONTAINING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2024-03-20 | — | — | EP | disclosed |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-6426335-B1 | ADMINISTERING COMPLEX OF NUCLEIC ACID LIGAND | GILEAD SCIENCES, INC. | 2002-07-30 | — | — | US | disclosed |
| US-6147204-A | COMPLEX FOR TARGETING THERAPEUTIC OR DIAGNOSTIC AGENTS TO PREFERENTIAL BIOLOGICAL TARGET | NEXSTAR PHARMACEUTICALS, INC. (US) | 2000-11-14 | — | — | US | disclosed |
| EP-1015629-A1 | BIOCONJUGATION OF OLIGONUCLEOTIDES | Proligo L.L.C. (US) | 2000-07-05 | — | — | EP | disclosed |
| US-6011020-A | THERAPEUTIC OR DIAGNOSTIC COMPLEX COMPRISED OF A NUCLEIC ACID LIGAND AND A POLYETHYLENE GLYCOL (PEG), WHEREIN SAID NUCLEIC ACID LIGAND IS COVALENTLY LINKED TO SAID PEG | NEXSTAR PHARMACEUTICALS, INC. (US) | 2000-01-04 | — | — | US | disclosed |
| EP-0957929-A1 | VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) NUCLEIC ACID LIGAND COMPLEXES | NeXstar Pharmaceuticals, Inc. (US) | 1999-11-24 | — | — | EP | disclosed |
| US-5859228-A | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes | NEXSTAR PHARMACEUTICALS, INC. (US) | 1999-01-12 | — | — | US | disclosed |
| WO-1998030720-A1 | BIOCONJUGATION OF OLIGONUCLEOTIDES | PROLIGO LLC (US) | 1998-07-16 | — | — | WO | disclosed |
| WO-1998018480-A1 | VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) NUCLEIC ACID LIGAND COMPLEXES | NEXSTAR PHARMACEUTICALS, INC. (US) | 1998-05-07 | — | — | WO | disclosed |
| EP-0824541-A1 | NUCLEIC ACID LIGAND COMPLEXES | NeXstar Pharmaceuticals, Inc. (US) | 1998-02-25 | — | — | EP | disclosed |
| WO-1996034876-A1 | NUCLEIC ACID LIGAND COMPLEXES | NEXSTAR PHARMACEUTICALS, INC. (US) | 1996-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | CD74, CD63, CD47 | GAA 438/4885ALDH1A1 868/4885CYP1A2 2119/4885 |
| US-20240131168-A1 | NAPHTHALENE RING-CONTAINING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | TP53, PKD1, KRAS | GAA 1393/4885ALDH1A1 592/4885CYP1A2 99/4885 |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | CD63, CD74, CD99 | GAA 529/4885ALDH1A1 1177/4885CYP1A2 2172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.